Breast Cancer Diagnostics Market To Reach $7.7 Billion By 2030

Breast Cancer Diagnostics Market Growth & Trends

The global breast cancer diagnostics market size is expected to reach USD 7.7 billion by 2030, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 7.4% from 2023 to 2030. The growth is largely attributable to the increasing geriatric population exposed to the risk of breast cancer and early detection coupled with increasing awareness about breast cancer.

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls. Rapid technological advancements are a major factor expected to drive the market over the coming years.

Companies are adopting strategies that allow them to use their resources to aid in the development of new products, as well as enhance their supply chain. In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company’s market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million. Biotheranostics is a commercial-stage molecular diagnostics provider for breast and metastatic cancers.

The increasing launch of predictive and companion diagnostic tests for breast cancer is expected to boost the market growth. Recent launches in the segment include BRACAnalysis CDx by Myriad Genetics, which received FDA approval in 2018 as breast cancer companion diagnostics. In May 2019, QIAGEN introduced therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for Novartis proprietary PIQRAY in guiding treatment decisions from tissue and liquid biopsy.

In January 2019, the Fujifilm Holdings Corporation introduced its Tomosynthesis Biopsy option for ASPIRE Cristalle mammography system. This technique was expected to enable physicians to detect breast cancers more efficiently compared to others by providing an enhanced 3D image and a digital mammogram.

However, there are specific risk factors associated with these imaging procedures. They involve administering high doses of fluorescent and barium contrast agents, as well as radiation exposure in the case of imaging and endoscopic procedures, which can cause several adverse effects such as nausea or diarrhea. The risks of ionizing radiation exposure associated with the use of CT, MRI, and X-rays, as well as the use of radioactive tracer injections in PET can limit the adoption of such screening procedures. Therefore, factors such as adverse effects of imaging act as a challenge for the companies in this market.

 Request a free sample copy or view report summary: Breast Cancer Diagnostics Market Report

Breast Cancer Diagnostics Market Report Highlights

• The imaging segment held the largest revenue share in 2022 and the blood tests segment is expected to grow at the fastest rate

• By product, the instrument-based products segment accounted for the largest revenue share in 2022 due to government initiatives such as mandatory screening in developed countries such as the U.S., Canada, and the U.K. for women above 45 years of age, increasing the overall testing and screening of breast cancer

• The platform-based products segment is expected to witness the fastest growth over the forecast period. These tests are mostly used for assessing the efficacy of chemotherapy and targeted therapy in women

• By application, the diagnostic and predictive segment dominated the market in 2022 and the prognostic segment is expected to witness the fastest CAGR over the forecast period due to increasing collaborations and efforts for advancements in diagnostics

• The hospitals and clinics segment dominated the market in 2022

• The medical labs and diagnostics centers segment is expected to witness the fastest CAGR over the forecast period due to an increase in platform-based testing such as NGS, and PCR

Breast Cancer Diagnostics Market Segmentation

Grand View Research has segmented the global breast cancer diagnostics market report based on type, product, application, end-use, and region

Breast Cancer Diagnostics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Imaging

• Biopsy

• Genomic Tests

• Blood Tests

• Others 

Breast Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Platform-based Products

  • Next-generation Sequencing

  • Microarrays

  • PCR

  • Others

• Instrument-based Products

  • Imaging

  • Biopsy

Breast Cancer Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Screening

• Diagnostic and Predictive

• Prognostic

• Research 

Breast Cancer Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Diagnostic Centers and Medical Laboratories

• Others 

Breast Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Breast Cancer Diagnostics Market

• Genomic Health (Exact Sciences Corporation)

• BD

• Danaher

• Koninklijke Philips N.V.

• QIAGEN

• Thermo Fisher Scientific Inc.

• Myriad Genetics, Inc.

• Argon Medical Devices, Inc.

• F. Hoffmann-La Roche Ltd.

• Hologic Inc.